Chemistry:Cintirorgon
From HandWiki
Cintirorgon (LYC-55716) is a drug which acts as a selective agonist of the receptor RAR-related orphan receptor gamma (RORγ). It was developed for the treatment of certain forms of cancer and is in early stage human clinical trials.[1][2][3][4][5]
References
- ↑ "Discovery of LYC-55716: A Potent, Selective, and Orally Bioavailable Retinoic Acid Receptor-Related Orphan Receptor-γ (RORγ) Agonist for Use in Treating Cancer". Journal of Medicinal Chemistry 64 (18): 13410–13428. September 2021. doi:10.1021/acs.jmedchem.1c00731. PMID 34499493.
- ↑ "RORγt agonist enhances anti-PD-1 therapy by promoting monocyte-derived dendritic cells through CXCL10 in cancers". Journal of Experimental & Clinical Cancer Research 41 (1). April 2022. doi:10.1186/s13046-022-02289-2. PMID 35459193.
- ↑ "RORγt agonist LYC-55716 potentiates IFN-α's efficacy in hepatocellular carcinoma through enhancing cytotoxicity of Tc17 cells and infiltration of CD8+ T cells". Biochemical Pharmacology 238. August 2025. doi:10.1016/j.bcp.2025.116963. PMID 40312017.
- ↑ "A Concise and Modular Approach to Generate Novel RORγ Agonists". Journal of Medicinal Chemistry 68 (15). August 2025. doi:10.1021/acs.jmedchem.5c00872. PMID 40677142.
- ↑ "A Novel RORγ-Selective Agonist Facilitates the Infiltration of Effector T Cells and Innate Immune Cells into Tumor Tissue, Demonstrating Antitumor Efficacy". Biological & Pharmaceutical Bulletin 48 (12). 2025. doi:10.1248/bpb.b25-00540. PMID 41338992.
 |  |
